Genetic testing can help deliver precision medicine to men with advanced prostate cancer
Genetic testing in men with advanced prostate cancer could pick up a significant proportion whose disease may be caused by inherited mutations in genes involved in repairing DNA damage, a major new study reveals.
Testing prostate cancer patients for mutations in key DNA repair genes could identify those who may benefit from precision treatments that specifically target DNA repair weaknesses in cancer cells.
Some 12 per cent of men with advanced prostate cancer in the study population were found to have inherited mutations in one of several genes involved in DNA repair – such as the breast cancer gene BRCA2.
The researchers, whose study is published in the prestigious journal the New England Journal of Medicine today (Wednesday), believe that genetic testing could form a valuable part of the treatment pathway for advanced prostate cancer.
A team at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust – with colleagues at seven other world-leading cancer centres in the US – used a simple saliva test to analyse the DNA of patients.
They examined the DNA code of 20 genes known to have a role in DNA repair in 692 men with advanced prostate cancer.
Some 12 per cent of men had at least one ‘germline’ mutation in a DNA repair gene – meaning an error that is either inherited or developed before birth. The most commonly defective gene was BRCA2, which was mutated in 5 per cent of men.
Men who have inherited mutations in certain DNA repair genes may benefit from treatment with new drugs called PARP inhibitors, which exploit weaknesses in the processes for DNA repair within cancer cells.
Where BRCA2 mutations are detected in men with advanced prostate cancer, the study opens up the possibility that relatives could also be tested for BRCA2 mutations. More research is needed to clarify the role of the other DNA repair genes in causing prostate cancer and the implications for testing.
The study is the largest of its kind to date, and the first to comprehensively analyse germline mutations in men with advanced, or metastatic, prostate cancer – where the disease has spread around the body.
The study was funded by the Prostate Cancer Foundation and Stand Up to Cancer, through a Movember and Prostate Cancer UK grant to The London Movember Centre of Excellence, through the Experimental Cancer Medicine Centre at The Institute of Cancer Research (ICR) and The Royal Marsden, and by Cancer Research UK, the Medical Research Council and the NIHR Biomedical Research Centre at The Royal Marsden and the ICR.
Professor Johann de Bono, Professor of Experimental Cancer Medicine at The Institute of Cancer Research, London, and Consultant Oncologist at The Royal Marsden NHS Foundation Trust, who led the study in the UK, said:
“Our study has shown that a significant proportion of men with advanced prostate cancer are born with DNA repair mutations – and this could have important implications for patients.
“Genetic testing for these mutations could identify men with advanced prostate cancer who may benefit from precision treatment. We could offer these men drugs such as PARP inhibitors, which are effective in patients with certain DNA repair mutations and are showing important anti-tumour activity in ongoing clinical trials.
“Where we find BRCA2 mutations, we could also offer genetic testing and counselling to relatives of the patient to consider how we can reduce their cancer risk. We also need to establish the impact of having DNA repair defects on survival in men with prostate cancer, and whether we can predict who will develop severe disease, so we can design new treatment strategies to cure this disease.”
Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:
“This valuable study has given us new insights into the causes of aggressive forms of prostate cancer that have spread round the body. It suggests testing for inherited DNA repair mutations could become an important stage in the treatment of men with advanced prostate cancer, by helping direct use of targeted cancer therapies.
“There is huge diversity in prostate cancers from patient to patient – some men live for decades with localised tumours, while in others cancers develop rapidly and spread round the body. Genetic markers that can detect the patients at high risk are desperately needed to improve men’s survival chances.”
For more information contact Claire Hastings on 020 7153 5380 or [email protected] For enquiries out of hours, please call 07595 963 613.
Notes to editors
Prostate cancer is the most common cancer in men in the UK. Around 47,300 new cases were diagnosed in 2013, and more than 10,000 men die from the disease each year – more than one man every hour.
The Institute of Cancer Research, London, is one of the world’s most influential cancer research organisations.
Scientists and clinicians at The Institute of Cancer Research (ICR) are working every day to make a real impact on cancer patients’ lives. Through its unique partnership with The Royal Marsden NHS Foundation Trust and ‘bench-to-bedside’ approach, the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top four centres for cancer research and treatment globally.
The ICR has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it is a world leader at identifying cancer-related genes and discovering new targeted drugs for personalised cancer treatment.
A college of the University of London, the ICR is the UK’s top-ranked academic institution for research quality, and provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations, charities and the general public.
The ICR’s mission is to make the discoveries that defeat cancer. For more information visit http://www.icr.ac.uk